Overview

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if a combination of neoadjuvant dutasteride and bicalutamide has the same efficacy and less toxicity than standard treatment with an LHRH agonist and bicalutamide for prostate cytoreduction prior to permanent implant brachytherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Québec, CHU de Québec
CHU de Quebec-Universite Laval

Collaborator:

GlaxoSmithKline

Treatments:

Bicalutamide
Dutasteride
Tamoxifen